Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Market Cap | $18,707 | $26,370 | $50,188 | $63,647 |
| - Cash | $11,867 | $17,193 | $10,967 | $16,623 |
| + Debt | $40 | $16 | $142 | $185 |
| Enterprise Value | $6,880 | $9,193 | $39,363 | $47,209 |
| Revenue | $1,768 | $1,200 | $1,086 | $493 |
| % Growth | 47.3% | 10.5% | 120.2% | – |
| Gross Profit | $1,749 | $1,157 | $1,073 | $474 |
| % Margin | 98.9% | 96.4% | 98.7% | 96.1% |
| EBITDA | -$7,167 | -$4,733 | -$6,107 | -$5,261 |
| % Margin | -405.4% | -394.4% | -562.1% | -1,066.3% |
| Net Income | -$7,176 | -$4,743 | -$6,107 | -$5,273 |
| % Margin | -405.9% | -395.2% | -562.1% | -1,068.8% |
| EPS Diluted | -0.007 | -0.007 | -0.009 | -0.008 |
| % Growth | -6.1% | 28.3% | -17.9% | – |
| Operating Cash Flow | -$5,370 | -$4,834 | -$5,606 | -$2,546 |
| Capital Expenditures | $3 | -$7 | -$7 | -$23 |
| Free Cash Flow | -$5,367 | -$4,841 | -$5,612 | -$2,568 |